ScholarIQanswers from OpenAlex & ORCID
Madan Jagasia
ResearcherPublications, citations & collaboration network
Madan Jagasia is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Madan Jagasia have?
ScholarIQindexed works
Madan Jagasia has 494 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Madan Jagasia have?
ScholarIQcitation count
Madan Jagasia has 23,796 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Madan Jagasia?
ScholarIQh-index
Madan Jagasia has an h-index of 70 in OpenAlex.
What is the i10-index of Madan Jagasia?
ScholarIQi10-index
Madan Jagasia has an i10-index of 193 in OpenAlex.
What is the ORCID of Madan Jagasia?
ScholarIQorcid
The ORCID for Madan Jagasia is on the source record.
What is the OpenAlex record for Madan Jagasia?
ScholarIQopenalex
The OpenAlex for Madan Jagasia is on the source record.
What are the most-cited papers on Madan Jagasia?
ScholarIQmost cited works
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
Madan Jagasia, Hildegard Greinix, Mukta Arora, Kirsten M. Williams, Daniel Wolff, Edward W. Cowen, Jeanne Palmer, Daniel J. Weisdorf, Nathaniel S. Treister, Guang‐Shing Cheng, Holly Kerr, Pamela Stratton, Rafael F. Duarte, George B. McDonald, Yoshihiro Inamoto, Afonso Celso Vigorito, Sally Arai, Manuel B. Datiles, David A. Jacobsohn, Theo Heller, Carrie L. Kitko, Sandra A. Mitchell, Paul J. Martin, Howard M. Shulman, Roy S. Wu, Corey Cutler, Georgia B. Vogelsang, Stephanie J. Lee, Steven Z. Pavletic, Mary E.D. Flowers
Risk factors for acute GVHD and survival after hematopoietic cell transplantation
Madan Jagasia, Mukta Arora, Mary E.D. Flowers, Nelson J. Chao, Philip L. McCarthy, Corey Cutler, Álvaro Urbano-Ispizúa, Steven Z. Pavletic, Michael Haagenson, Mei-Jie Zhang, Joseph H. Antin, Brian J. Bolwell, Christopher Bredeson, Jean‐Yves Cahn, Mitchell S. Cairo, Robert Peter Gale, Vikas Gupta, Stephanie J. Lee, Mark R. Litzow, Daniel J. Weisdorf, Mary M. Horowitz, Theresa Hahn
Ibrutinib for chronic graft-versus-host disease after failure of prior therapy
David B. Miklos, Corey Cutler, Mukta Arora, Edmund K. Waller, Madan Jagasia, Iskra Pusic, Mary E.D. Flowers, Aaron C. Logan, Ryotaro Nakamura, Bruce R. Blazar, Yunfeng Li, Stephen Chang, Indu Lal, Jason A. Dubovsky, Danelle F. James, Lori Styles, Samantha Jaglowski
Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study
Corey Cutler, Stephanie J. Lee, Sally Arai, Marcello Rotta, Behyar Zoghi, Aleksandr Lazaryan, Aravind Ramakrishnan, Zachariah DeFilipp, Amandeep Salhotra, Wanxing Chai‐Ho, Rohtesh S. Mehta, Trent Wang, Mukta Arora, Iskra Pusic, Ayman Saad, Nirav N. Shah, Sunil Abhyankar, Carlos Bachier, John P. Galvin, Annie Im, Amelia Langston, Jane L. Liesveld, Mark Juckett, Aaron C. Logan, Levanto Schachter, Asif Alavi, Dianna S. Howard, Harlan W. Waksal, John L. Ryan, David Eiznhamer, Sanjay Aggarwal, Jonathan Ieyoub, Olivier Schueller, Laurie Green, Zhongming Yang, Heidi Krenz, Madan Jagasia, Bruce R. Blazar, Steven Z. Pavletic
Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study
Jason Chesney, Karl D. Lewis, Harriet M. Kluger, Omid Hamid, Eric D. Whitman, Sajeve Thomas, Martin Wermke, Mike Cusnir, Evidio Domingo‐Musibay, Giao Q. Phan, John M. Kirkwood, Jessica C. Hassel, Marlana Orloff, James Larkin, Jeffrey S. Weber, Andrew J.S. Furness, Nikhil I. Khushalani, Theresa Medina, Michael E. Egger, Friedrich Graf Finckenstein, Madan Jagasia, Parameswaran Hari, Giri Sulur, Wen Shi, Xiao Wu, Amod A. Sarnaik